Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 8/20 | 0.74 |
| ▸ | POLB | P06746 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | GPR183 | P32249 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1952477 | 0.86 | ALDH1A1 (0.75) | POLBALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2712996 | 0.85 | FKBP1A (0.74) | FKBP1APOLBALDH1A1MEN1KMT2A | |
| SCHEMBL13534672 | 0.85 | FKBP1A (0.92) | FKBP1APOLBALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL8320871 | 0.84 | ALDH1A1 (0.79) | FKBP1APOLBALDH1A1MEN1KMT2A | |
| SCHEMBL11659648 | 0.83 | SMN1; SMN2 (0.70) | FKBP1APOLBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL335195 | 0.82 | FKBP1A (0.74) | FKBP1APOLBALDH1A1MEN1KMT2A | |
| SCHEMBL12359393 | 0.82 | FKBP1A (1.00) | FKBP1APOLBALDH1A1MEN1KMT2A | |
| SCHEMBL5692472 | 0.82 | ALDH1A1 (1.00) | FKBP1APOLBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2554461 | 0.82 | FKBP1A (0.70) | FKBP1APOLBALDH1A1MEN1KMT2A | |
| SCHEMBL15134814 | 0.82 | ALDH1A1 (0.78) | POLBALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| EP-4581024-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024047135-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-03-07 | — | — | WO | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | FKBP1A 371/4885POLB 1777/4885ALDH1A1 289/4885 |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | KRAS, NRAS, HRAS | FKBP1A 1893/4885POLB 3194/4885ALDH1A1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.